|
Press Release |
31 May 2013 |
("LiDCO" or the "Company")
Grant of share options
LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, today announces that on 30 May 2013 the board of directors of the Company approved the below grants to two directors of the Company of options ("Options") to subscribe for new ordinary shares of 0.5p each ("Ordinary Shares"), pursuant to the remuneration policy described in the Company's annual report and accounts for the year ended 31 January 2013.
|
Director |
Number of Options granted |
Total number of Options now held |
Number of Ordinary Shares Held |
%age of the Company's issued Ordinary Shares |
|
|
|
|
|
|
|
Dr Terry O'Brien |
4,477,711 |
4,905,106 |
11,516,563 |
5.94% |
|
Paul Clifford |
1,029,296 |
1,971,227 |
659,660 |
0.34% |
The Options are exercisable at 13.5 pence per Ordinary Share, vest on 30 May 2016, subject to the achievement of certain profitability targets, and thereafter expire if not exercised within a seven year period.
- Ends -
For further information, please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien (CEO) |
Tel:+44 (0)20 7749 1500 |
|
Paul Clifford (Finance Director) |
|
|
Theresa Wallis (Chairman) |
|
FinnCap |
|
|
Geoff Nash / Henrik Persson Stephen Norcross (broking) |
Tel: +44 (0)20 7220 0500 |
Media enquiries:
|
Abchurch |
|
|
Adam Michael / Simone Elviss / Jamie Hooper |
Tel: +44 (0) 20 7398 7719 |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
Key Products:
|
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) |
|
|
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: |
|
|
· |
early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
|
· |
quantification of hemodynamic response, |
|
· |
guidance on effective delivery of fluids to ensure the right amount at the right time |
|
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. |
|
|
LiDCO Unity Software: The software incorporated into LiDCOrapidv2 will allow the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter and add the convenience of CNSystem's* continuous non-invasive blood pressure monitoring. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. |
|
* CNAPTM is a trademark of CNSystems Medizintechnik AG.
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.